The GIP-induced peripheral promotion of positive energy balance is likely to be far less effective than the GLP- 1/GIP dual agonist's direct action on the central nervous system, which results in satiety and weight loss
Clinical studies have shown that, on average, individuals can lose around 10-15% of their body weight with consistent use of Ozempic over several months
Preclinical evidence supports the role of GLP-1RAs in alleviating neuropathic pain through the modulation of microglial activity, inflammatory cytokine production and -endorphin release [63, 65, 68, 70,71,72,73,74]
For tirzepatide (Zepbound) Jastreboff and colleagues reported in the New England Journal of Medicine in 2022 that at maximal doses, the percent of individuals reporting side effects were as follows: Nausea 31.0% Diarrhea 23.0% Vomiting 12.2% Constipation 11.7% Bettge and colleagues conducted a study published in Diabetes, Obesity, and Metabolism in 2017 that showed that individuals who were taking metformin while taking a GLP-1 were more likely to have side effects, especially nausea and vomiting
Efficacy and safety of oral Orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study
4, 2015, pp
